Chuan-ming Y. Hao - Publications

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.

Journal: The New England journal of medicine

Published: June 05, 2026

Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease-2025 Update.

Journal: Nephrology (Carlton, Vic.)

Published: March 23, 2025

Executive Summary of the Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease-2025 Update.

Journal: Nephrology (Carlton, Vic.)

Published: March 23, 2025

Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China.

Journal: Renal failure

Published: July 23, 2024

Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: June 19, 2024

Relapse Risk in Patients with Membranous Nephropathy after Inactivated COVID-19 Vaccination.

Journal: Nephron

Published: April 23, 2024

Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic.

Journal: Clinical kidney journal

Published: April 10, 2024

Case report: BTK inhibitors is effective in type II mixed cryoglobulinemia with wild-type MyD88.

Journal: Frontiers in immunology

Published: February 27, 2024

Retroperitoneal leakage as an important cause of acquired ultrafiltration decline in peritoneal dialysis: clinical characteristics and related risk factors.

Journal: Journal of nephrology

Published: December 07, 2023

Aggressive treatment may be needed for idiopathic membranous nephropathy with focal segmental glomerulosclerosis lesions.

Journal: Revista da Associacao Medica Brasileira (1992)

Published: November 23, 2023

Widening the Prostacyclin Paradigm: Tissue Fibroblasts Are a Critical Site of Production and Antithrombotic Protection.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: October 12, 2023

Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I 2 Receptor.

Journal: Journal of the American Society of Nephrology : JASN

Published: April 24, 2023